# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-216791
Filing Date
2026-05-11
Accepted
2026-05-11 16:13:50
Documents
65
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | eikn-20260331.htm iXBRL | 10-Q | 2577905
2 | EX-31.1 | eikn-ex31_1.htm | EX-31.1 | 17618
3 | EX-31.2 | eikn-ex31_2.htm | EX-31.2 | 17574
4 | EX-32.1 | eikn-ex32_1.htm | EX-32.1 | 10545
5 | EX-32.2 | eikn-ex32_2.htm | EX-32.2 | 10278
6 | GRAPHIC | img119830300_0.jpg | GRAPHIC | 996985
| Complete submission text file | 0001193125-26-216791.txt |  | 11333839

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | eikn-20260331.xsd | EX-101.SCH | 1075722
69 | EXTRACTED XBRL INSTANCE DOCUMENT | eikn-20260331_htm.xml | XML | 1461488

Mailing Address 230 HARRIET TUBMAN WAY MILLBRAE CA 94030
Business Address 230 HARRIET TUBMAN WAY MILLBRAE CA 94030 341-777-0566
Eikon Therapeutics, Inc. (Filer) CIK: 0001861123 (see all company filings)

EIN.: 842807586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43085 | Film No.: 26963357
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)